8YY — Biolidics Balance Sheet
0.000.00%
- SG$31.10m
- SG$32.56m
- SG$0.78m
Annual balance sheet for Biolidics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 10.7 | 3.96 | 5.03 | 0.183 | 0.295 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.399 | 0.349 | 0.682 | 0.153 | 0.352 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 12.9 | 6.11 | 5.92 | 0.43 | 0.667 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.41 | 1.19 | 0.168 | 0.252 | 0.065 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 18.8 | 11.4 | 6.09 | 0.682 | 4.67 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.29 | 2.42 | 6.01 | 1.92 | 1.91 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.5 | 9.09 | 7.78 | 2.67 | 2.94 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 8.27 | 2.33 | -1.69 | -1.99 | 1.73 |
Total Liabilities & Shareholders' Equity | 18.8 | 11.4 | 6.09 | 0.682 | 4.67 |
Total Common Shares Outstanding |